Form 4: Neurocrine CCO Benevich Reports Future RSU Vesting

Neurocrine Biosciences' Chief Commercial Officer, Eric Benevich, reported the future vesting of restricted stock units and subsequent share withholding for tax obligations.

Summary

• Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc. (NBIX), reported transactions related to his beneficial ownership, scheduled for January 31, 2026.
• On January 31, 2026, 2,294 shares of common stock are to be acquired upon the vesting of restricted stock units (RSUs) at a price of $0.
• Concurrently, 1,292 shares are to be disposed of at $136.06 per share to satisfy tax withholding requirements related to the RSU vesting.
• No shares are to be sold by Mr. Benevich; the disposition is solely for tax purposes.
• Following these transactions, Mr. Benevich will beneficially own 52,755 shares of Neurocrine Biosciences common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and alignment of interests, with no discretionary sales by the insider.

Positives

• The scheduled vesting of 2,294 restricted stock units indicates continued long-term incentive alignment for the Chief Commercial Officer.
• The disposition of shares is solely for tax withholding, not a discretionary sale by the insider.

Negatives

• A scheduled reduction of 1,292 shares in direct beneficial ownership due to tax withholding.

Future Outlook

This Form 4 reports a scheduled future transaction related to executive compensation and does not contain broader forward-looking statements or guidance regarding company performance or strategy.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax withholding are standard compensation practices for executives in the biotechnology and pharmaceutical industries, aligning executive incentives with long-term company performance. This type of transaction is common and generally not indicative of a change in company strategy or performance.

Comparison to Industry Standards

• The RSU vesting schedule, with tranches over several years, is a common practice in the biotechnology sector, similar to compensation structures seen at companies like Biogen or Gilead Sciences, which use long-term equity incentives to retain key talent.
• The withholding of shares for tax purposes upon vesting is a standard, non-discretionary event, consistent with practices across publicly traded companies globally, including those in the S&P 500.

Related Party Transactions

• The RSU grant and vesting are related-party transactions as they involve an executive, but they are part of standard compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event. It reflects continued alignment of executive incentives with shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 reports a routine RSU vesting and tax withholding transaction by a key executive, scheduled for a future date. It does not indicate any discretionary buying or selling activity that would suggest a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Neurocrine Biosciences, NBIX, Eric Benevich, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Chief Commercial Officer, Beneficial Ownership, Tax Withholding